Thursday, October 01, 2020 12:46:08 PM
Versus brings its real-world prizing software to a new vertical – healthcare – as life science companies look to improve clinical testing diversity, compliance
[/I]
Versus Systems Partners With Predictmedix
LOS ANGELES, October 1, 2020--Versus Systems, Inc. (“Versus”) (CSE:VS) (CSE:VS.CN) (OTCQB:VRSSF) (FRANKFURT:BMVA) today signed an agreement with Predictmedix, Inc. (CSE:PMED)(OTCQB:PMEDF), a medical software company that integrates Artificial Intelligence “AI” into healthcare testing technology. The agreement is to bring Versus’ proprietary rewards platform to the healthcare vertical – allowing healthcare providers, Contract Research Organizations (CROs), and life science companies to use rewards to recruit and retain a broader range of patients, and to promote compliance in testing medical therapies. These products, for use primarily by CROs, academic medical centers and those in the clinical trials markets, will enter a market that Fortune Business Insights estimates at $40 Billion USD annually.[1]
Predictmedix will use Versus’s patented rewards and engagement engine to incentivize users and patients to take steps in their treatment. In the case of clinical trials, this may include rewarding patients for joining certain trials, as well as for complying with trial protocols. According to Deloitte, recruiting, retention, and compliance are central issues in the clinical trial space with over 40% of patients not adhering to trial protocols.[2] The Versus IP allows for remote data collection, real-time feedback, and a rewards-based engagement that could change patient behaviors and outcomes - saving time and money, and also improving healthcare outcomes by providing more complete trial data.
https://www.fortunebusinessinsights.com/industry-reports/contract-research-organization-cro-services-market-100864
https://www2.deloitte.com/us/en/blog/health-care-blog/2020/improve-clinical-trial.html[/url
Recent VS News
- Versus Systems to Participate in the 36th Annual ROTH Conference • GlobeNewswire Inc. • 03/14/2024 08:05:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 09:15:32 PM
- Form S-4 - Registration of securities, business combinations • Edgar (US Regulatory) • 02/16/2024 10:32:54 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:15:25 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:04:05 PM
- Versus Systems Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 09:05:43 PM
- Versus Systems Announces Annual General Meeting Results • GlobeNewswire Inc. • 01/03/2024 09:05:00 PM
- Versus Systems Announces 1-For-16 Reverse Stock Split to Aid Compliance with Nasdaq Listing Requirements • GlobeNewswire Inc. • 12/22/2023 09:05:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 12/07/2023 08:48:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/06/2023 10:19:22 PM
- Versus Systems Announces Strategic Investment from Cronus Equity Capital Group, LLC • GlobeNewswire Inc. • 11/24/2023 01:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 10/20/2023 08:58:38 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/17/2023 09:20:36 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 10/16/2023 09:14:05 PM
- Versus Systems Inc. Announces Pricing of $3.0 Million Public Offering • GlobeNewswire Inc. • 10/13/2023 03:55:30 PM
- Form F-1/A - Registration statement for certain foreign private issuers: [Amend] • Edgar (US Regulatory) • 10/12/2023 06:52:34 PM
- Form F-3/A - Registration statement by foreign private issuers: [Amend] • Edgar (US Regulatory) • 09/22/2023 08:00:51 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM